The City University of New York (CUNY), Lawrence Livermore National Laboratory, and Near Infrared Imaging, have released the “Vein-Eye” camera. The Vein-Eye provides enhanced visualisation of veins when drawing blood or placing IVs in a patient’s arm or hand. The Vein-Eye is a non-contact medical device that displays real-time video for accurate vein punctures.
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
The first patient has been enrolled in ETNA-AF-Europe (Edoxaban treatment in routine clinical practice – atrial fibrillation – Europe), and ETNA-VTE-Europe (Edoxaban treatment in routine clinical practice – venous thromboembolism – Europe) has commenced.
Results of the landmark CATCH (Comparison of Acute Treatments in Cancer Haemostasis) study were published in The Journal of American Medical Association (JAMA), comparing innohep (tinzaparin), a low-molecular weight heparin (LMWH), with warfarin in patients with cancer-associated thrombosis.
Kimihiko Kichikawa, Department of Radiology at Nara Medical University in Japan, reported two-year results of the Zilver PTX post-market surveillance (PMS) study on 27 September 2015, in Lisbon, Portugal. Kichikawa presented initial target data on lesion revascularisation at Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015.
Stentys, a medical technology company commercialising the Self-Apposing coronary stent, announced on 28 September 2015 that the company’s drug-eluting stent received the CE mark for treatment of below-the-knee (BTK) arteries, making Stentys’ product the first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.
On the back of these results, Stephan Müller-Hülsbeck announced the commencement of an international multicentre randomised controlled trial that will compare the Eluvia drug-eluting vascular stent system (Boston Scientific) with Zilver PTX, the drug-eluting stent system from Cook Medical. The principal investigators will be Müller-Hülsbeck (Flensburg, Germany) and William Gray (New York, USA).
BTG announced promising data on Sunday, 27 September, for DC BeadM1, supporting the efficacy and tolerability of doxorubicin-eluting DC BeadM1in the treatment of patients diagnosed with liver-confined hepatocellular carcinoma (HCC). The preliminary results of the single-centre, retrospective, single-arm study, in which patients achieved a median overall survival of 41 months, were presented during the 2015 CIRSE (Cardiovascular and Interventional Radiological Society of Europe) conference in Lisbon, Portugal. While DC Bead drug-eluting bead is backed by clinical safety and efficacy data in over 3,000 HCC patients, DC BeadM1 is a more recent addition to the product range. Designed with a narrow size distribution, so that it can travel deeper into the vasculature of the tumour, while also allowing for a more concentrated drug delivery, DC BeadM1 offers a new standard-of-care and a much more targeted therapy than conventional chemoembolisation for the treatment of HCC.
The 2015 annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in September in Lisbon, Portugal, marks a special occasion—it will be 30 years since a key meeting in Austria in 1985, in which a merger of two societies led to the birth of CIRSE. Interventional radiology on the continent has come a long way in these years following its modest, but promising, beginnings.
Interventional News recommends that readers watch Edward (Ted) Diethrich’s moving video that draws attention to the dangers of working with radiation. The video (below) follows the renowned American cardiovascular surgeon’s journey in which he discovers that he has a brain tumour. Simultaneously fact-filled and moving, the viewer is drawn into the story of the talented young surgeon with superb skills and training who was an early adopter of the endovascular approach, which meant that he was chronically exposed to ionising radiation, despite the use of protective gear.
The results of a research study indicate that interventional cardiologists receive “very high” radiation exposure levels to the left side of the head specifically when performing fluoroscopically guided invasive cardiovascular procedures.
A new European‐wide observational study to prospectively gather data on patients treated with irinotecan‐loaded microspheres has been launched by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). The CIRSE Registry for LifePearl microspheres (CIREL) will begin early in 2016.
Research published in the Journal of the American College of Radiology in June suggests that hospital costs to place a chest port were significantly lower in the interventional radiology suite than in the operating room. Patients who were treated by radiology and surgery did not show a significantly different rate of complications and/or infections.
Medtronic plc has announced that it has acquired Medina Medical, a Menlo Park, California, USA-based and privately-held medical device company focused on commercialising state-of-the-art treatments for vascular abnormalities of the brain including cerebral aneurysms.
Surefire, a developer of a new class of direct-to-tumour treatment delivery devices employed in minimally invasive chemoembolization and radioembolization procedures, announced that the company has received US510(k) FDA clearance for Precision. The infusion technology’s unique expandable tip increases drug delivery into the tumour while protecting healthy tissue.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos